{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:22:41Z","timestamp":1776421361111,"version":"3.51.2"},"reference-count":97,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundo Europeu de Desenvolvimento Regional (FEDER)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"CHAIR in Onco-Innovationfrom Faculty of Medicine, University of Porto (FMUP)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Lung cancer is the deadliest cancer worldwide, exhibiting the highest incidence rate among all cancer types. Poor outcomes often characterize this cancer as it is commonly diagnosed in advanced stages due to its unspecific symptoms. After diagnosis, the therapeutic choice is a crucial stage that profoundly affects patients\u2019 survival. Treatment choices for lung cancer must be made carefully, acknowledging the histological type and genetic characteristics of the tumor. Non-small cell lung cancer, the most common and complex type, has a high mutational burden, making next-generation sequencing (NGS) essential for identifying specific mutations and guiding treatment. With several approved targeted therapies already available, this approach highlights the critical role of personalized medicine in lung cancer care. Despite the current therapeutic pipeline, research trying to develop new tailored drugs considering individual patient characteristics has evolved over the years. This article aims to outline the current therapeutic approach for each type of lung cancer and present the latest insights into emerging therapies, highlighting the role of personalized medicine in enhancing treatment outcomes and improving patients\u2019 quality of life.<\/jats:p>","DOI":"10.3390\/cancers17050725","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:53:06Z","timestamp":1740124386000},"page":"725","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lung Cancer Therapy: The Role of Personalized Medicine"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5324-8826","authenticated-orcid":false,"given":"Raquel","family":"Ramos","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Le\u00e7a do Balio, Portugal"}]},{"given":"Concei\u00e7\u00e3o Souto","family":"Moura","sequence":"additional","affiliation":[{"name":"Pathology Laboratory, Unilabs Portugal, Rua Manuel Pinto de Azevedo 173, 4100-321 Porto, Portugal"}]},{"given":"Mariana","family":"Costa","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Le\u00e7a do Balio, Portugal"}]},{"given":"Nuno Jorge","family":"Lamas","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Le\u00e7a do Balio, Portugal"},{"name":"Anatomic Pathology Service, Pathology Department, Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio (CHUdSA), Largo Professor Abel Salazar, 4099-001 Porto, Portugal"},{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, Campus de Gualtar, University of Minho, Rua da Universidade, 4710-057 Braga, Portugal"}]},{"given":"Renato","family":"Correia","sequence":"additional","affiliation":[{"name":"Technology & Innovation Department, Unilabs Portugal, Rua Manuel Pinto de Azevedo 173, 4100-321 Porto, Portugal"}]},{"given":"Diogo","family":"Garcez","sequence":"additional","affiliation":[{"name":"Technology & Innovation Department, Unilabs Portugal, Rua Manuel Pinto de Azevedo 173, 4100-321 Porto, Portugal"}]},{"given":"Jos\u00e9 Miguel","family":"Pereira","sequence":"additional","affiliation":[{"name":"Radiology Department, Unilabs Portugal, Rua de Diogo Botelho 485, 4150-255 Porto, Portugal"}]},{"given":"Thomas","family":"Lindahl","sequence":"additional","affiliation":[{"name":"Unilabs Group Services, Succursale d\u2019Unilabs, Laboratoire d\u2019Analyses M\u00e9dicales SA, Rue de Lausanne 15, 1201 Geneva, Switzerland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0708-6874","authenticated-orcid":false,"given":"Carlos","family":"Sousa","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Le\u00e7a do Balio, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J.E.M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/today."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00408-023-00661-3","article-title":"Lung Cancer in Never Smokers: Delving into Epidemiology, Genomic and Immune Landscape, Prognosis, Treatment, and Screening","volume":"201","author":"Daylan","year":"2023","journal-title":"Lung"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer Progress and Priorities: Lung Cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e001021","DOI":"10.1136\/esmoopen-2020-001021","article-title":"Lung cancer symptoms at diagnosis: Results of a nationwide registry study","volume":"5","author":"Provencio","year":"2020","journal-title":"ESMO Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"230190","DOI":"10.1183\/20734735.0190-2023","article-title":"Lung cancer screening: Where do we stand?","volume":"20","author":"Hardavella","year":"2024","journal-title":"Breathe"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3322\/caac.21811","article-title":"Screening for lung cancer: 2023 guideline update from the American Cancer Society","volume":"74","author":"Wolf","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ramos, R., Moura, C.S., Costa, M., Lamas, N.J., Correia, R., Garcez, D., Pereira, J.M., Sousa, C., and Vale, N. (2024). Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes. J. Pers. Med., 14.","DOI":"10.3390\/jpm14050446"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7150\/ijms.34739","article-title":"Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications","volume":"16","author":"Marino","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","article-title":"Translational Implications of Tumor Heterogeneity","volume":"21","author":"Quezada","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/CM9.0000000000002693","article-title":"Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation","volume":"137","author":"Guo","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nooreldeen, R., and Bach, H. (2021). Current and Future Development in Lung Cancer Diagnosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168661"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1634\/theoncologist.2020-0193","article-title":"Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer","volume":"25","author":"Melosky","year":"2020","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Acheampong, E., Abed, A., Morici, M., Bowyer, S., Amanuel, B., Lin, W., Millward, M., and Gray, E.S. (2020). Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells, 9.","DOI":"10.3390\/cells9112393"},{"key":"ref_16","first-page":"100561","article-title":"Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment","volume":"4","author":"Lo","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gad.314815.118","article-title":"POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer","volume":"32","author":"Huang","year":"2018","journal-title":"Genes Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73745","DOI":"10.18632\/oncotarget.20572","article-title":"Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer","volume":"8","author":"McColl","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/labinvest.2014.157","article-title":"Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic","volume":"95","author":"Schalper","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Li, H., Zhao, P., Tian, L., Lu, Y., Wang, X., Shao, W., and Cheng, Y. (2024). Advances in biomarkers for immunotherapy in small-cell lung cancer. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1490590"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S633","DOI":"10.1016\/S0959-8049(16)31739-7","article-title":"3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC)","volume":"51","author":"Calvo","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/jco.2015.33.15_suppl.7502","article-title":"Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028","volume":"33","author":"Ott","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)","volume":"7","author":"Altan","year":"2019","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2018.36.15_suppl.8506","article-title":"Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158","volume":"36","author":"Chung","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in Patients with Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study","volume":"35","author":"Ott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Dvorkin","year":"2019","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","article-title":"Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032","volume":"14","author":"Ready","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"x43","DOI":"10.1093\/annonc\/mdy511.004","article-title":"Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331","volume":"29","author":"Reck","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331\u2606","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_37","unstructured":"(2024, September 20). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)\u2014Small Cell Lung Cancer. Available online: https:\/\/www.nccn.org\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"153303381878390","DOI":"10.1177\/1533033818783904","article-title":"Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database","volume":"17","author":"Shioyama","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijrobp.2016.10.041","article-title":"Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer","volume":"97","author":"Verma","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cllc.2017.03.009","article-title":"Outcomes of Stereotactic Body Radiotherapy for T1-T2N0 Small Cell Carcinoma According to Addition of Chemotherapy and Prophylactic Cranial Irradiation: A Multicenter Analysis","volume":"18","author":"Verma","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/SLA.0000000000002287","article-title":"Long-term Survival After Surgery Compared with Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer","volume":"268","author":"Yang","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gondi, V., Pugh, S., Mehta, M., Wefel, J.S., Tom\u00e9, W., Sun, A., Videtic, G., Lok, B.H., Yoon, H.A., and Heinzerling, J.H. (2023). Primary Endpoint Results of NRG CC003: Phase IIR\/III Trial of Prophylactic Cranial Irradiation (PCI) with or without Hippocampal Avoidance (HA) for Small Cell Lung Cancer (SCLC). Int. J. Radiat. Oncol. Biol. Phys., 117.","DOI":"10.1016\/j.ijrobp.2023.08.028"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1183\/09031936.00105009","article-title":"Treatment of extensive-stage small cell lung carcinoma: Current status and future prospects","volume":"35","author":"Demedts","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_47","unstructured":"(2025, February 10). FDA Grants Accelerated Approval to Tarlatamab-Dlle for Extensive Stage Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Champiat","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_52","unstructured":"(2025, February 10). FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e32899","DOI":"10.1097\/MD.0000000000032899","article-title":"Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment","volume":"102","author":"Alduais","year":"2023","journal-title":"Medicine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00432-019-03079-8","article-title":"The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients","volume":"146","author":"Wang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e2355331","DOI":"10.1001\/jamanetworkopen.2023.55331","article-title":"Epidemiology and Outcomes of Non\u2013Small Cell Lung Cancer in South Korea","volume":"7","author":"Jung","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biocel.2016.07.011","article-title":"Management of non-small cell lung cancer in the era of personalized medicine","volume":"78","author":"Rocco","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.apsb.2018.04.005","article-title":"Personalized medicine in non-small cell lung cancer: A review from a pharmacogenomics perspective","volume":"8","author":"Jiang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_60","first-page":"300","article-title":"Personalized Treatment for Patients with Lung Cancer","volume":"120","author":"Schuler","year":"2023","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2020.07.009","article-title":"Precision medicine in non-small cell lung cancer: Current applications and future directions","volume":"84","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae Insights: Non\u2013Small Cell Lung Cancer, Version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3322\/caac.21774","article-title":"Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide","volume":"73","author":"Fox","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_65","first-page":"201","article-title":"Molecular profiling in lung cancer","volume":"15","author":"Nagl","year":"2022","journal-title":"MEMO Mag. Eur. Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100260","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): A glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets","year":"2021","journal-title":"ESMO Open"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"Marreaud","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_75","unstructured":"(2024, September 20). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)\u2014Non-Small Cell Lung Cancer. Available online: https:\/\/www.nccn.org\/."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"107522","DOI":"10.1016\/j.pharmthera.2020.107522","article-title":"Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights","volume":"210","author":"Meador","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Casagrande, G.M.S., Silva, M.D.O., Reis, R.M., and Leal, L.F. (2023). Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032505"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Pujol, N., Heeke, S., Bontoux, C., Boutros, J., Ili\u00e9, M., Hofman, V., Marquette, C.-H., Hofman, P., and Benzaquen, J. (2022). Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101684"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion\u2013Mutated Non\u2013Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_82","unstructured":"J&J Innovative Medicine (2024, September 23). RYBREVANT\u00ae (Amivantamab-Vmjw) in Combination with Chemotherapy Is the First FDA Approved Therapy for First-Line Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Available online: https:\/\/www.janssen.com\/rybrevantr-amivantamab-vmjw-combination-chemotherapy-first-fda-approved-therapy-first-line-treatment."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"TPS9132","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9132","article-title":"CHRYSALIS-2: A phase 1\/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC","volume":"39","author":"Shu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8619","DOI":"10.1200\/JCO.2024.42.16_suppl.8619","article-title":"Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1\/2 METalmark study","volume":"42","author":"Spira","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_86","unstructured":"(2024, September 23). A Study of Combination Therapy with Amivantamab and Cetrelimab in Participants with Metastatic Non-Small Cell Lung Cancer (PolyDamas), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05908734."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1200\/JCO.2023.41.16_suppl.9126","article-title":"Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study\u2014Updated safety and identification of the recommended phase 2 dose","volume":"41","author":"Minchom","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"LBA8612","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8612","article-title":"Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study","volume":"42","author":"Lim","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cllc.2013.08.001","article-title":"A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: The princess margaret hospital phase II consortium","volume":"15","author":"Laurie","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ramos, R., and Vale, N. (2024). Dual Drug Repurposing: The Example of Saracatinib. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084565"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"26090","DOI":"10.18632\/oncotarget.4636","article-title":"Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status","volume":"6","author":"Formisano","year":"2015","journal-title":"Oncotarget"},{"key":"ref_93","first-page":"102","article-title":"Tumor-derived exosomes: Immune properties and clinical application in lung cancer","volume":"5","author":"Wu","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1007\/s00018-019-03233-y","article-title":"The biological functions and clinical applications of exosomes in lung cancer","volume":"76","author":"Chen","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e12828","DOI":"10.1111\/cpr.12828","article-title":"Role of exosomal microRNAs in lung cancer biology and clinical applications","volume":"53","author":"Hu","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7150\/ijbs.38414","article-title":"Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor","volume":"16","author":"Wang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/resp.13915","article-title":"Pulmonary toxicity of systemic lung cancer therapy","volume":"25","author":"Long","year":"2020","journal-title":"Respirology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/725\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:39:18Z","timestamp":1760027958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":97,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17050725"],"URL":"https:\/\/doi.org\/10.3390\/cancers17050725","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}